Both directly bind to the core ligase sub‐complex of CRL4, inhibit its E3 ligase activity in vitro and in cell‐based assays, and exhibit antitumor activity in vitro and in vivo, with KH‐4‐43 binding more strongly to the catalytic core and generally being more efficacious in killing cancer cells.3 Here, IL17RB is linked to cancer.